ixekizumab
ixekizumab: sourced relationships with 1 company · 4 clinical trials tracked · 1 FDA decision.
ixekizumab evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could ixekizumab → LLY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ELI LILLY & Co (LLY) Reported 2016-03-22 · Current development: unknownSource Psoriatic Arthritis; Juvenile Psoriatic Arthritis; Psoriasis | Phase 4 |
| ELI LILLY & Co (LLY) Reported 2016-03-22 · Current development: unknownSource For the treatment of adults and pediatric patients aged 6 ye… | Approved |
Clinical Trial Registry Records (4)
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
Primary endpoint: Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss
Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)
Primary endpoint: Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction
Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)
Primary endpoint: Percentage of Participants Who Simultaneously Achieved American College of Rheumatology (ACR) ACR50 and at Least a 10% Weight Reduction
Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Primary endpoint: Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 (Ixekizumab - OLT Period)
FDA Decisions1 records
Frequently asked questions
Which companies have sourced relationships with ixekizumab?
ixekizumab has dated SEC/FDA relationship records for ELI LILLY & Co.
How many clinical trials involve ixekizumab?
BioSniper tracks 4 clinical trials involving ixekizumab.
What is ixekizumab's latest FDA decision?
The most recent tracked FDA decision for ixekizumab is Approval, dated March 22, 2016.